healthcare

healthcare Articles

Amyris shares jumped on Friday after the firm announced that it has successfully delivered on its first milestone for its cannabinoid partner, Lavvan.
Tricida shares jumped on Thursday after the firm announced results from its chronic kidney disease study.
Proteon Therapeutics shares were absolutely crushed on Thursday after the firm announced results from its late-stage trial in patients with chronic kidney disease.
Amyris shares ended Wednesday on a very positive note despite the broad markets lagging. The company reiterated guidance for its coming quarter as well as saying that it will discuss its future...
This is one of those mergers that is not getting the warm fuzzy feeling that management teams love to see.
Axsome shares jumped on Wednesday after the firm gave an update from the FDA regarding its AXS-05 for the treatment of major depressive disorder.
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected marijuana stocks were mixed.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
It seems that cannabis stocks such as Canopy Growth and Tilray have become more normalized in the United States and legislation is on the way.
Curis shares jumped when the firm announced that it entered into an agreement to sell rights to a portion of royalty revenues on worldwide net sales of Erivedge.
Biogen shares made a slight gain early on Monday after the firm made an SEC filing indicating that it will be buying back a sizable amount of stock.
Biogen shares were crushed in Thursday’s session after the firm announced that it would be discontinuing its late-stage trial for Alzheimer’s disease.
Pfizer is looking to collaborate with Vivet on the development of its proprietary treatment for Wilson disease.
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.